Table 1 Baseline demographics
Baseline characteristics | Included subjects (n=10) |
|---|---|
Age in years | 67 (7) |
Gender | 60% women, 40% men |
Hypertension | 40% |
Coronary artery disease | 0% |
Hyperlipidemia | 10% |
Baseline cognitive assessment | |
Mini-Mental State Examination | 24 (3) |
Cognitive Assessment Screening Test | 29.6 (5) |
Clinical Dementia Rating scale | 1 (0.47) |
ADAS-cog 13 | 31 (7) |
Serology | |
C-reactive protein (mg/L) | 1.4 (1.8) |
Low-density lipoprotein (mg/dL) | 137.2 (26.7) |
High-density lipoprotein (mg/dL) | 58.2 (19.2) |
Total cholesterol (mg/dL) | 223.9 (32.3) |
Triglycerides (mg/dL) | 133.1 (66.9) |
Creatine phosphokinase (U/L) | 69 (36.86) |
Thyroid-stimulating hormone (mU/L) | 2.92 (2.33) |
Vitamin B12 (pg/mL) | 506 (359) |
Erythrocyte sedimentation rate (mm/h) | 8.8 (5.9) |
International normalized ratio | 1.0 (0.1) |
Medication use | |
Donepezil or rivastigmine | 80% |
Memantine | 40% |
Psychotropic use | 70% |
Anticholinergic drug usea | 30% |
Apolipoprotein E (APOE) genotyping (n=9) | |
APOE-3,3 | 1 (11%) |
APOE-3,4 | 5 (56%) |
APOE-4,4 | 3 (33%) |
Cerebral spinal fluid phosphorylated tau (n=7) | |
High (>68 pg/mL) | 3(43%) |
Intermediate (55–67 pg/mL) | 1 (14%) |
Normal (<54 pg/mL) | 3 (43%) |